Clinical trial
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in…
NCT00000635 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00000635 |
|---|---|
| Title | Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine |
| Official title | Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Glaxo Wellcome Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Herpes Simplex, HIV Infections |
| Intervention type | Drug |
| Interventions | Trifluridine, Bacitracin zinc/Polymyxin B sulfate |
| Enrollment | 25 |
| Completion | Apr 1, 1992 |
| First posted | Aug 31, 2001 |
| Last update posted | Nov 2, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: